1. Introduction {#sec1-ijms-19-00465}
===============

Atherosclerotic cardiovascular diseases, such as coronary artery disease (CAD) and stroke, are a leading cause of mortality worldwide \[[@B1-ijms-19-00465]\]. The prevalence of traditional risk factors for CAD, such as diabetes, hypertension, dyslipidemia, obesity, and others, has been increasing worldwide, with consequent increases in the rates of coronary and cerebrovascular events \[[@B1-ijms-19-00465]\]. Atherosclerosis is characterized by a complex interaction of vascular endothelial injury, inflammation with monocyte adhesion to endothelial cells (ECs), lipid deposition with macrophage foam cells, and the migration and proliferation of vascular smooth muscle cells (VSMCs) accompanied by extracellular matrix (ECM) remodeling \[[@B2-ijms-19-00465]\].

We have investigated the atheroprotective properties of a large number of novel human endogenous peptides, such as salusin-α, heregulin-β1, omentin-1, catestatin-1, urocortin-1, stanniocalcin-1, and incretins (glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide) \[[@B3-ijms-19-00465],[@B4-ijms-19-00465],[@B5-ijms-19-00465],[@B6-ijms-19-00465],[@B7-ijms-19-00465],[@B8-ijms-19-00465],[@B9-ijms-19-00465]\]. Now we are paying more attention to tumor necrosis factor-stimulated gene-6 (TSG-6) as an anti-atherogenic protein \[[@B10-ijms-19-00465]\]. There has been recent progress in TSG-6 studies. The present article reviews the recent literature and introduces our new data regarding the role of TSG-6 in the pathogenesis of atherosclerosis and as a biomarker and novel potential therapeutic target for atherosclerotic cardiovascular diseases.

2. Structure of TSG-6 {#sec2-ijms-19-00465}
=====================

TSG-6, which maps to human chromosome 2q23.3, was originally identified as the sixth gene product induced by tumor necrosis factor-α (TNF-α) in human fibroblasts \[[@B11-ijms-19-00465]\], and is also called Tnfaip6 or Tnfip6 (accession numbers: CAD12353, CAD13434). TSG-6 cDNA encodes a polypeptide of 277 amino acids, including an N-terminal cleavable signal peptide of 17 amino acids. The molecular size of the mature, fully glycosylated TSG-6 protein is 31,203 Da. The N-terminal half of the TSG-6 protein shows 36--40% homology to the Link module, which is a conserved sequence in hyaluronan-binding proteins, such as CD44, cartilage link protein, and G1 domains of aggrecan and versican \[[@B12-ijms-19-00465]\]. The C-terminal half of the molecule (CUB domain) shows 30% homology to the complement C1r A chain \[[@B12-ijms-19-00465]\]. Human and murine TSG-6 are \>94% identical \[[@B12-ijms-19-00465]\]. The specific receptors for TSG-6 have not yet been identified.

3. Expression and Regulation of TSG-6 {#sec3-ijms-19-00465}
=====================================

TSG-6 is not usually expressed but is rapidly upregulated in many different cell types, including monocytes/macrophages, dendritic cells, leukocytes, ECs, VSMCs, fibroblasts, synoviocytes, chondrocytes, and proximal tubular epithelial cells upon exposure to inflammatory mediators, such as interleukin (IL)-1, interferon-γ, TNF-α, lipopolysaccharide (LPS), and prostaglandin E~2~ \[[@B13-ijms-19-00465],[@B14-ijms-19-00465],[@B15-ijms-19-00465]\] as well as growth factors, such as fibroblast growth factor, epidermal growth factor, and transforming growth factor-β, and mechanical stimuli in vitro \[[@B12-ijms-19-00465],[@B16-ijms-19-00465]\]. Expression of TSG-6 is also known to be markedly upregulated by exposure to high glucose and fatty acid (palmitic acid) concentrations in human umbilical vein endothelial cells (HUVECs) \[[@B17-ijms-19-00465]\]. In contrast, TSG-6 expression is suppressed by anti-inflammatory cytokines, such as IL-4 or IL-10 either directly or via inhibition of LPS/Toll-like receptor (TLR)-induced cell activation \[[@B15-ijms-19-00465]\].

TSG-6 is released from the secretory granules of neutrophils and mast cells as well as macrophages and a wide variety of stromal cell types \[[@B12-ijms-19-00465],[@B15-ijms-19-00465],[@B18-ijms-19-00465],[@B19-ijms-19-00465],[@B20-ijms-19-00465]\]. Mesenchymal stem cells (MSCs) also secrete TSG-6 to repair tissue injury and wounds and reduce inflammation \[[@B21-ijms-19-00465]\]. Several lines of evidence have shown that TSG-6 is detected in synovial fluids and joint tissues from patients with rheumatoid arthritis and osteoarthritis \[[@B13-ijms-19-00465],[@B22-ijms-19-00465]\] and in sera of patients with bacterial sepsis, systemic lupus erythematosus, and CAD \[[@B10-ijms-19-00465],[@B23-ijms-19-00465]\].

4. Roles of TSG-6 {#sec4-ijms-19-00465}
=================

Based on structural homologies, TSG-6 binds to a large number of components of the ECM including hyaluronan, heparin, heparan sulfate, thrombospondins-1 and -2, fibronectin, and pentraxin-3 \[[@B24-ijms-19-00465],[@B25-ijms-19-00465]\]. These interactions primarily act to stabilize or remodel the ECM \[[@B25-ijms-19-00465]\]. Several lines of evidence have suggested that TSG-6 may play a crucial role in ECM formation, inflammatory cell migration, cell proliferation, and developmental processes \[[@B26-ijms-19-00465]\]. TSG-6 is known as a potent inhibitor of neutrophil migration and can modulate the protease network by inhibiting plasmin \[[@B24-ijms-19-00465]\]. TSG-6 also increases hyaluronan synthesis in airway smooth muscle cells \[[@B26-ijms-19-00465]\]. TSG-6 has a chondroprotective effect, with reduced loss of cartilage proteoglycan and less accumulation of matrix metalloproteinase (MMP) and aggecanase-generated aggrecan fragments \[[@B27-ijms-19-00465]\]. TSG-6 is locally coexpressed with its ligand pentraxin-3 that cooperates with TSG-6 in ECM assembly \[[@B28-ijms-19-00465]\]. TSG-6 suppresses the inhibitory effects of pentraxin-3 on fibroblast growth factor-2-mediated angiogenesis \[[@B28-ijms-19-00465]\].

TSG-6 has been shown to exert anti-inflammatory effects in experimental models of arthritis, corneal wounding, acute myocardial infarction, and acute cerebral infarction \[[@B29-ijms-19-00465],[@B30-ijms-19-00465],[@B31-ijms-19-00465],[@B32-ijms-19-00465]\]. In transgenic mice, inactivation of the gene increases inflammatory responses \[[@B33-ijms-19-00465]\], and over-expression of the gene decreases inflammatory responses \[[@B34-ijms-19-00465]\]. Administration of recombinant TSG-6 decreases LPS-induced inflammation (IL-6 and interferon-γ), and improves arthritis and memory after traumatic brain injury in several murine models \[[@B25-ijms-19-00465],[@B29-ijms-19-00465],[@B35-ijms-19-00465],[@B36-ijms-19-00465]\]. The half-life of TSG-6 after intravenous injection into mice is up to 0.2 h \[[@B25-ijms-19-00465]\].

In addition, TSG-6 secreted by human adipose tissue-derived MSCs ameliorates dextran sulfate sodium-induced colitis by inducing anti-inflammatory M2 macrophage polarization in mice \[[@B37-ijms-19-00465]\]. Co-incubation of human adipose tissue-derived MSCs suppresses LPS-induced IL-1β secretion from THP-1 monocytes via increasing TSG-6 expression \[[@B38-ijms-19-00465]\]. Knocking down TSG-6 in MSCs abrogates the inhibitory effects of MSCs on inflammatory neovascularization and monocyte/macrophage infiltration \[[@B39-ijms-19-00465]\]. The intraarticular injection of MSCs increases TSG-6 expression in joint cartilage and inhibits monoiodoacetate-induced arthritis in rats \[[@B40-ijms-19-00465]\].

Several lines of evidence have recently shown the atheroprotective effects of TSG-6. TSG-6 exerts anti-atherosclerotic effects on all the three cellular players in the pathogenesis of atherosclerosis, such as ECs, macrophages, and VSMCs ([Figure 1](#ijms-19-00465-f001){ref-type="fig"}). Although the receptors for TSG-6 have not yet been clarified, it is almost certain that the receptors are present in three types of vascular cells. Next, the present review introduces the anti-atherosclerotic effects of TSG-6 on vascular cells in vitro, animal models in vivo, and human clinical data, in this order.

5. Effects of TSG-6 in ECs {#sec5-ijms-19-00465}
==========================

TSG-6 inhibits leukocyte adhesion to HUVECs and HUVEC-derived EA.hy926 ECs and leukocyte migration \[[@B41-ijms-19-00465],[@B42-ijms-19-00465]\]. TSG-6 suppresses the proliferation of EA.hy926 ECs \[[@B10-ijms-19-00465]\]. TSG-6 suppresses LPS-induced expression of monocyte chemotactic protein-1 (MCP-1), vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in HUVECs \[[@B10-ijms-19-00465]\]. In addition, MSCs improve glucolipotoxicity via TSG-6 production in HUVECs \[[@B17-ijms-19-00465]\].

6. Effects of TSG-6 in Monocytes/Macrophages {#sec6-ijms-19-00465}
============================================

TSG-6, either directly or through a complex with hyaluronan, binds to CD44 and downregulates TLR-2/nuclear factor-κB (NF-κB) and upregulates cyclooxygenase-2, a negative regulator of inflammation, in mouse macrophages \[[@B43-ijms-19-00465],[@B44-ijms-19-00465]\]. TSG-6 inhibits cell proliferation and LPS-induced release of inflammatory cytokines, such as IL-1β, IL-6, and TNF-α, via c-Jun N-terminal kinase (JNK) and p38 pathways in rat macrophages \[[@B45-ijms-19-00465]\]. TSG-6 also suppresses the inflammatory M1 phenotype and LPS-induced TNF-α production in human monocyte-derived macrophages \[[@B10-ijms-19-00465]\]. TSG-6 suppresses oxidized low-density lipoprotein-induced foam cell formation associated with downregulation of acyl-coenzyme A:cholesterol acyltransferase-1 and CD36 in human monocyte-derived macrophages \[[@B10-ijms-19-00465]\].

7. Effects of TSG-6 in VSMCs {#sec7-ijms-19-00465}
============================

TSG-6 suppresses angiotensin II-induced migration and proliferation of human aortic smooth muscle cells via c-Src/JNK/NF-κB pathways \[[@B10-ijms-19-00465]\]. In contrast, TSG-6 enhances rat VSMC proliferation \[[@B46-ijms-19-00465]\]. TSG-6 also increases the expression of collagen-1, collagen-3, MMP-2, and tissue inhibitor of metalloproteinase-2 in human aortic smooth muscle cells \[[@B10-ijms-19-00465]\]. These findings indicate that TSG-6 suppresses atherosclerosis and restenosis after angioplasty and induces vascular remodeling.

8. Effects of TSG-6 on Atherosclerotic Lesion Development in ApoE-Deficient Mice {#sec8-ijms-19-00465}
================================================================================

Infusing TSG-6 (100 μg/mouse) into ApoE-deficient mice for four weeks retards the development of atherosclerotic lesions in the entire surface area of the aorta \[[@B10-ijms-19-00465]\]. In atheromatous plaques in the aortic sinus wall, vascular inflammation (pentraxin-3) and monocyte/macrophage and VSMC contents are decreased ([Figure 2](#ijms-19-00465-f002){ref-type="fig"}D,F,H) by TSG-6 infusion. The ratio of macrophage contents/VSMC contents (a surrogate marker of plaque instability) is reduced by TSG-6 infusion ([Figure 2](#ijms-19-00465-f002){ref-type="fig"}I). TSG-6 also increases collagen fibers within atheromatous plaques \[[@B10-ijms-19-00465]\]. These findings indicate that TSG-6 stabilizes atheromatous plaques. In addition, four-week infusion of anti-TSG-6 neutralizing antibody (50 μg/mouse) into ApoE-deficient mice significantly enhances the development of atherosclerotic lesions in the entire aortic surface area and plaque burden in the aortic sinus ([Figure 3](#ijms-19-00465-f003){ref-type="fig"}A,B).

Four-week infusion of TSG-6 (100 μg/mouse) into ApoE-deficient mice decreases the inflammatory M1 phenotype and the levels of inflammasome proteins such as MCP-1, NF-κB, C-reactive protein, and apoptosis-associated speck-like protein containing a caspase recruitment domain in exudate peritoneal macrophages \[[@B10-ijms-19-00465]\]. TSG-6 also decreases plasma levels of total cholesterol with a tendency to increase high-density lipoprotein cholesterol in ApoE-deficient mice \[[@B10-ijms-19-00465]\].

9. Roles of TSG-6 in Animal Atherosclerosis and Vascular Restenosis in Wire-Injury and Vein Graft Models {#sec9-ijms-19-00465}
========================================================================================================

Several animal studies have shown the expression of TSG-6 in atherosclerotic lesions in vivo \[[@B10-ijms-19-00465],[@B46-ijms-19-00465],[@B47-ijms-19-00465]\]. TSG-6 is localized in rat neointima after arterial injury and rabbit carotid atherosclerotic plaques \[[@B46-ijms-19-00465],[@B47-ijms-19-00465]\]. In our study, TSG-6 was expressed in atherosclerotic plaques in the aorta and neointimal lesions in the femoral artery after wire injury in ApoE-deficient mice ([Figure 4](#ijms-19-00465-f004){ref-type="fig"}B,J). The expression of TSG-6 is consistent with vascular inflammation and macrophages in atheromatous plaques ([Figure 4](#ijms-19-00465-f004){ref-type="fig"}B,D,E) and neointimal thickness (VSMCs) in obstructive arteries following injury ([Figure 4](#ijms-19-00465-f004){ref-type="fig"}I,J).

TSG-6 inhibits the inflammatory response of transplanted vein grafts in rats and reduces vascular injury by downregulating the JNK and P38 pathways \[[@B45-ijms-19-00465]\]. TSG-6 suppresses vascular restenosis in the venous bridge with decreasing VSMC proliferation, macrophage infiltration, and plasma levels of inflammatory cytokines, such as IL-1β, IL-6, and TNF-α, via JNK and p38 pathways \[[@B45-ijms-19-00465]\].

10. Expression of TSG-6 in Human Arteriosclerotic Lesions and Aneurysms {#sec10-ijms-19-00465}
=======================================================================

Recent studies have shown the presence of TSG-6 expression in human coronary atherosclerotic plaques and abdominal aortic aneurysms \[[@B10-ijms-19-00465],[@B48-ijms-19-00465]\]. The expression of TSG-6 is almost absent in normal and non-stenotic coronary arteries from non-CAD and CAD patients respectively \[[@B10-ijms-19-00465]\]. In the stenotic coronary arteries from CAD patients, TSG-6 is highly expressed in the fibrous cap within atherosclerotic plaques \[[@B10-ijms-19-00465]\]. In addition, the expression of TSG-6 is observed in the tunica media of human abdominal aortic aneurysms \[[@B48-ijms-19-00465]\]. These findings suggest that TSG-6 is produced to counteract the progression of atherosclerotic lesions and to stabilize vulnerable plaques and aneurysms.

11. Potential Biomarker for CAD {#sec11-ijms-19-00465}
===============================

Plasma TSG level was significantly higher in 135 patients with angiographically proven CAD (acute coronary syndrome) than the level in 47 non-CAD subjects \[[@B10-ijms-19-00465]\] ([Figure 5](#ijms-19-00465-f005){ref-type="fig"}A). Based on the receiver operating characteristic (ROC) curve ([Figure 5](#ijms-19-00465-f005){ref-type="fig"}B), 9.5 ng/mL is adopted as the cutoff value that shows a higher true-positive rate (sensitivity) with a low false-positive rate (1-specificity). The area under the curve (AUC) value is 0.68 ([Figure 4](#ijms-19-00465-f004){ref-type="fig"}B). The sensitivity and specificity for detecting CAD using this cutoff value were 52% and 30%, respectively. Therefore, plasma TSG-6 level could be a reliable biomarker for detecting CAD.

Among 135 patients with CAD, 32 patients had major adverse cardiovascular events (MACE), defined as cardiovascular death, heart failure, acute myocardial infarction, post-infarction angina, and ischemic stroke, during a period of four years. Plasma TSG-6 level at the onset of acute coronary syndrome tended to be increased in CAD patients with MACE compared with those without MACE, but there was no significant difference ([Figure 6](#ijms-19-00465-f006){ref-type="fig"}A). Furthermore, the prevalence rate of MACE was significantly higher in CAD patients with TSG-6 ≥ 19 ng/mL (40%, 10/25 cases) than the rate in those with TSG-6 \< 19 ng/mL (20%, 22/110 cases) ([Figure 6](#ijms-19-00465-f006){ref-type="fig"}B). The finding suggests that high plasma levels of TSG-6 may induce downregulation of its receptor, leading to ineffective MACE prevention in CAD patients.

12. Treatment of Atherosclerotic Diseases with TSG-6 {#sec12-ijms-19-00465}
====================================================

There are several major therapeutic strategies against atherosclerosis and related diseases using TSG-6. One is the enhancement of endogenous TSG-6 by MSC infusion and the another is the supplementation with exogenous TSG-6. (1) Silencing TSG-6 in the administered MSCs results in loss of therapeutic activity, whereas administering exogenous TSG-6 rescues the therapeutic activity \[[@B21-ijms-19-00465]\]. MSC therapeutic activities in other animal models of disease including cerebral ischemia, myocardial infarction, type 1 diabetes, peritoneal adhesions, and experimental autoimmune encephalomyelitis were observed to be dependent on TSG-6 \[[@B31-ijms-19-00465],[@B32-ijms-19-00465],[@B49-ijms-19-00465],[@B50-ijms-19-00465],[@B51-ijms-19-00465],[@B52-ijms-19-00465]\]. (2) For replacement therapy of exogenous TSG-6, a great amount of recombinant human TSG-6 is needed. The recombinant TSG-6 is synthesized in *Escherichia coli*, wheat germ, insect cells, Chinese hamster ovary (CHO) cells, and mouse myeloma cells. CHO cell-derived TSG-6 has a longer half-life compared with mouse myeloma cell-derived TSG-6 in vivo \[[@B25-ijms-19-00465]\].

It is especially important to elucidate the putative receptor for TSG-6, which provides an investigation of its agonist as a new drug target. Otherwise, it is important to clarify a biologically active fragment that has inhibitory effects against atherosclerosis among the 260 amino acids in TSG-6 protein (excluding the signal peptide), and further to develop derivatives or analogs based on the TSG-6 protein for preventing and treating atherosclerosis. Because infusion and injection are not convenient for patients, oral administration is a more suitable method. However, TSG-6 protein is digested after oral administration. Therefore, nanocapsules have received a great amount of attention as a drug delivery method \[[@B53-ijms-19-00465]\]. Encapsulation methods are beneficial for protecting polypeptides against the digestive environment, thereby promoting absorption and delivery to target organs \[[@B53-ijms-19-00465]\]. Due to their small size, these particles are able to pass only through the increased endothelial gaps due to injury and blood vessel damage in atherosclerotic arteries. Nanocapsules including TSG-6 analogs would be useful for oral administration.

However, manipulating plasma TSG-6 level as a potential therapeutic strategy should be considered with caution. If the putative TSG-6 receptors are downregulated in CAD patients, simply infusing TSG-6 would not be effective. Further treatments improving TSG-6 resistance should be developed in the future.

13. Conclusions {#sec13-ijms-19-00465}
===============

The above findings indicate that TSG-6 slows the development of atherosclerotic lesions by decreasing plasma total cholesterol levels, inflammatory responses of ECs and macrophages, macrophage foam cell formation, and the migration and proliferation of VSMCs. In addition, TSG-6 contributes to plaque stability by promoting collagen production by VSMCs in the fibrous cap. Thus, endogenous TSG-6 enhancement and exogenous TSG-6 replacement treatments are expected to emerge as a new line of therapy against atherosclerosis and its related CAD. The results presented here also provide insights into the potential use of TSG-6 as a biomarker for CAD. These findings may strengthen the clinical utility of TSG-6 in the diagnosis and treatment of atherosclerotic cardiovascular diseases.
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![Mechanisms underlying the atheroprotective effects of tumor necrosis factor-stimulated gene-6 (TSG-6). This figure illustrates the suppressive effects of TSG-6 on atherosclerotic plaque formation in the arterial wall. TSG-6 prevents atherosclerosis by suppressing the inflammatory responses in endothelial cells (ECs) and macrophages, oxidized low-density lipoprotein (LDL)-induced foam cell formation in macrophages, and the migration and proliferation of vascular smooth muscle cells (VSMCs). TSG-6 increases the production of collagen-1 and -3 by VSMCs. Abbreviations: ACAT1 = acyl-coenzyme A:cholesterol acyltransferase-1; ABCA1 = ATP-binding cassette transporter A1; CE = cholesterol ester; ICAM-1 = intercellular adhesion molecule-1; MCP-1 = monocyte chemotactic protein-1; Mo = monocyte; MΦ = macrophage; ROS = reactive oxygen species; VCAM-1 = vascular cell adhesion molecule-1.](ijms-19-00465-g001){#ijms-19-00465-f001}

![Effects of TSG-6 on atheromatous plaque progression and phenotype in ApoE-deficient mice. Four-week infusion of TSG-6 (100 μg/mouse, GenWay Biotech, San Diego, CA, USA) or saline (control) using osmotic mini-pumps was performed in 17-week-old ApoE-deficient mice fed a high cholesterol diet. Atheromatous plaques (**A**,**B**); vascular inflammation (**C**,**D**); macrophage contents (**E**,**F**); and VSMC contents (**G**,**H**) were assessed by staining with Oil Red O (Wako Pure Chemical Industries, Osaka, Japan), anti-pentraxin-3 antibody (Bioss Antibodies, Woburn, MA, USA), anti-MOMA-2 antibody (Millipore, Billerica, MA, USA), or anti-α-SMA antibody (Sigma, St. Louis, MO, USA), respectively. Hematoxylin was used for nuclear staining. Bar = 100 μm. The markers of plaque instability, such as high levels of pentraxin-3 expression and the increased ratio of macrophage contents (μm^2^)/VSMC contents (μm^2^) within atheromatous plaques (**I**), were compared between 21-week-old mice infused with saline (*n* = 13) and TSG-6 (*n* = 9). Data are presented as mean ± SEM. Unpaired Student's *t* test was used for statistical analysis. *p* = 0.1453. These results are unpublished data from our previous experiments \[[@B10-ijms-19-00465]\].](ijms-19-00465-g002){#ijms-19-00465-f002}

![Effects of endogenous TSG-6 decreases on the development of atherosclerotic lesions in ApoE-deficient mice. Four-week infusion of an anti-TSG-6 neutralizing antibody (50 μg/mouse, R&D Systems, Minneapolis, MN, USA) or saline (control) using osmotic mini-pumps was performed in 17-week-old ApoE-deficient mice fed a high cholesterol diet. Atherosclerotic lesions were stained with Oil Red O (Wako Pure Chemical Industries, Osaka, Japan). The atherosclerotic lesions were measured in the whole aortic tree. Plaque burden is expressed as a percentage relative to the entire cross section of the aortic sinus wall. Bar = 500 μm. Atherosclerotic lesions in the entire aortic surface area (**A**) and plaque burden (**B**) are increased in mice infused with anti-TSG-6 neutralizing antibody (*n* = 3) than those infused with saline (*n* = 5). Data are presented as mean ± SEM. Unpaired Student's *t* test was used for statistical analysis. (**A**) \* *p* = 0.0085; (**B**) *p* = 0.3124. These results are unpublished data from our new experiments.](ijms-19-00465-g003){#ijms-19-00465-f003}

![Expression of TSG-6 in atherosclerotic and restenotic lesions in ApoE-deficient mice. TSG-6 is expressed at high levels in aortic atherosclerotic lesions (**A**--**G**) and femoral artery restenotic lesions after wire injury (**H**--**J**) in ApoE-deficient mice fed a high-cholesterol diet. Tissues were immunostained with Oil Red O (Wako Pure Chemical Industries, Osaka, Japan; (**A**)); anti-TSG-6 antibody (Bioworld Technology, St. Louis Park, MN, USA; (**B**,**J**)); anti-podocalyxin antibody (Life Technologies, Carlsbad, CA, USA; (**C**)); anti-pentraxin-3 antibody (Bioss Antibodies, Woburn, MA, USA; (**D**)); anti-MOMA-2 antibody (Millipore, Billerica, MA, USA; (**E**)); anti-α-SMA antibody (Sigma, St. Louis, MO, USA; (**F**,**I**)); Masson's Trichrome (Muto Pure Chemicals, Tokyo, Japan; (**G**)); and Elastica-Van Gieson (Muto Pure Chemicals; (**H**)). Hematoxylin was used for nuclear staining. Bar = 100 μm. (**C**) Podocalyxin is used as an EC marker. (**G**) Masson's Trichrome is used to stain collagen fibers in blue. Panels (**A**--**G**) show unpublished data from our previous experiments \[[@B10-ijms-19-00465]\], and panels (**H**--**J**) show unpublished data from our new experiments.](ijms-19-00465-g004){#ijms-19-00465-f004}

![Biomarker of CAD using plasma TSG-6 levels at the onset of acute coronary syndrome. (**A**) Plasma TSG-6 levels are significantly higher in 135 CAD patients than 47 non-CAD subjects. Data are shown as median (center line in box) with 25th percentile (lower line of box), 75th percentile (upper line in box), 10th percentile (bars below box), and 90th percentile (bars above box). Unpaired Student's *t* test was used for statistical analysis. \* *p* = 0.0013. The graph was modified from the graph shown in our previous report (Watanabe et al., Atheroprotective Effects of Tumor Necrosis Factor--Stimulated Gene-6; JACC: Basic to Translational Science, **2016**, *6*, 494--509, permitted by Elsevier) \[[@B10-ijms-19-00465]\]. (**B**) The receiver operating characteristic (ROC) curve analysis indicates the cutoff value of plasma TSG-6 for detecting CAD. The arrow shows the cutoff value (9.5 ng/mL) chosen to gain a relatively higher true-positive rate (sensitivity) with a lower false-positive rate (1-specificity). The area under the curve (AUC) value is 0.68. The results are unpublished data from our previous study \[[@B10-ijms-19-00465]\].](ijms-19-00465-g005){#ijms-19-00465-f005}

![Prediction of prognosis using plasma TSG-6 levels at onset of CAD. Among 135 patients with acute coronary syndrome, 32 patients had major adverse cardiovascular events (MACE) including cardiovascular death, heart failure, acute myocardial infarction, post-infarction angina, and ischemic stroke during a period of four years after onset. The follow-up period was 50.0 ± 0.57 months. (**A**) Plasma TSG-6 levels tended to increase in CAD patients with MACE compared with those without MACE. Data are presented as mean ± SEM. Unpaired Student's *t* test was used for statistical analysis. *p* = 0.6109; (**B**) Prevalence rate of MACE (+) was significantly higher in CAD patients with TSG-6 ≥ 19 ng/mL (40%, 10/25 cases) than those with TSG-6 \< 19 ng/mL (20%, 22/110 cases). Chi-squared test was used for statistical analysis. \* *p* = 0.0338. These results are unpublished data from our follow-up study based on our previous report \[[@B10-ijms-19-00465]\].](ijms-19-00465-g006){#ijms-19-00465-f006}
